Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Gastroenterology. 2018 Oct 18;156(2):461–476.e1. doi: 10.1053/j.gastro.2018.09.058

Figure 3. HDV Life Cycle and Therapeutic Targets.

Figure 3.

Myrcludex-B attempts was designed to block entry of HDV into hepatocytes (A). REP2055 and REP2139-Ca were designed to inhibit HBsAg secretion (B). Lonafarnib inhibits HDV prenylation, required for virus packaging and secretion (C).